



This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit (s). Each participant should claim only those hours of credit that have actually been spent in the educational activity.



Organised by:
Academic Medical Center, Amsterdam
Course Director:
Prof John JP Kastelein

EBAC ACCREDITED SATELLITE SYMPOSIUM TO BE HELD DURING ESC 2018, MUNICH, GERMANY

LDL-c: Done deal, next epigenetics?



SATURDAY, AUGUST 25, 2018 • 15:30 – 16:30 HRS, BRUSSELS - VILLAGE 4

In co-operation with



Physicians' Academy
for Cardiovascular Education

Supported by an unrestricted educational grant from Resverlogix.

"In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities."



EBAC Accredited Satellite Symposium to be held during ESC 2018, Munich, Germany

LDL-c: Done deal, next epigenetics?

SATERDAY, AUGUST 25, 2018, 15:30 – 16:30 HRS • BRUSSELS - VILLAGE 4

AGENDA

Co-chairmen

Kausik Ray, MD – London, United Kingdom

Ulrich Laufs, MD – Leipzig, Germany

15:30 – 15:35

Introduction

Ulrich Laufs, MD – Leipzig, Germany

15:35 – 15:50

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

Erik Stroes, MD – Amsterdam, The Netherlands

15:50 – 16:10

Understanding epigenetics: The potential rationale for BET inhibition in management of CVD

Jorge Plutzky, MD – Boston, USA

16:10 – 16:25

A clinical view on BET inhibition in targeting residual risk in CVD and diabetes

Kausik Ray, MD

16:25 – 16:30

Discussion & summary

Kausik Ray, MD

Ulrich Laufs, MD

Educational objectives:

- To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
- To understand the origin of the high residual cardiovascular risk in patients with diabetes and CVD
- To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD
- To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

For information please visit the Physicians' Academy for Cardiovascular Education (PACE) foundation at www.pace-cme.org